Publication Reports

Featured

Novartis to Acquire Avidity Biosciences for $12 Billion

Novartis AG will acquire Avidity Biosciences for USD 72.00 per share in cash, valuing the company at approximately USD 12.0 billion. Avidity will sepa...

Select your product of interest

Thank you! Your request has been received.

Featured

Novartis to Acquire Avidity Biosciences for $12 Billion

Latest Merger & Acquisitions

Novartis to Acquire Avidity Biosciences for $12 Billion

Innovent and Takeda Partner to Develop Next-Gen IO and ADC Therapies

Boehringer Ingelheim and AimedBio Collaborate to Advance Novel ADC Therapy for Broad Range of Cancers

Biocon Biologics and Civica Expand Partnership to Launch Insulin Glargine for U.S. Diabetes Patients

Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion

MaxCyte and Moonlight Bio Partner to Advance T Cell Therapies for Solid Tumors

Elutia Closes BioEnvelope Business Sale to Boston Scientific for $88 Million, Focuses on NXT-41x for Breast Reconstruction Infections

Other Merger & Acquisitions Updates

Novartis to Acquire Avidity Biosciences for $12 Billion

Innovent and Takeda Partner to Develop Next-Gen IO and ADC Therapies

Boehringer Ingelheim and AimedBio Collaborate to Advance Novel ADC Therapy for Broad Range of Cancers

Biocon Biologics and Civica Expand Partnership to Launch Insulin Glargine for U.S. Diabetes Patients

Novo Nordisk to Acquire Akero Therapeutics for up to $5.2 Billion

MaxCyte and Moonlight Bio Partner to Advance T Cell Therapies for Solid Tumors

Elutia Closes BioEnvelope Business Sale to Boston Scientific for $88 Million, Focuses on NXT-41x for Breast Reconstruction Infections

Roche to Acquire 89bio for MASH Therapy Development

Novartis Acquires Tourmaline Bio for $1.4 Billion, Expanding Cardiovascular Pipeline with Pacibekitug

Zydus and Synthon Partner for Ozanimod Capsules in the US Market

Polpharma Biologics and MS Pharma Partner to Commercialize Biosimilars in MENA

Servier and IDEAYA Biosciences Partner to Develop Darovasertib for Uveal Melanoma

LakeShore Biopharma Receives Revised Acquisition Proposal

AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder

AbbVie Acquires Capstan Therapeutics and its Novel CAR-T Therapy Candidate

AleraCare and PURE Healthcare to Merge, Creating a Leading Ambulatory Infusion Platform

Melinta Therapeutics Acquired by CorMedix for $300 Million

CorMedix to Acquire Melinta Therapeutics, Expanding its Specialty Pharmaceutical Portfolio

Demetra Acquires OrthoFundamentals and Launches Global Spine Division

Sanofi Acquires Rights to Arrowhead's Plozasiran for Hypertriglyceridemia in Greater China

Mallinckrodt and Endo Merger Creates Global Therapeutics Leader

Hengrui Pharma and GSK Partner to Develop Up to 12 Innovative Medicines

Adaptimmune Sells Cell Therapies to US WorldMeds for $55 Million

Gate Bioscience and Lilly Partner to Develop Molecular Gate Medicines

Thermo Fisher and Sanofi Expand Partnership: Acquisition of Sterile Drug Manufacturing Site

Repare Therapeutics Outlicenses Lunresertib to Debiopharm

Cantargia Licenses CAN10 IL1RAP Immunology Program to Otsuka Pharmaceutical

Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up mRNA Manufacturing

Merck Acquires Verona Pharma for $10 Billion, Expanding COPD Treatment Portfolio

Chugai and Gero Partner to Develop Novel Therapies for Age-Related Diseases

Ligand Completes Merger with Channel Therapeutics, Launching ZELSUVMI™ for Molluscum Contagiosum

EnChannel Medical Acquires Acutus Medical's AcQMap™ Electrophysiology Assets

Biofrontera Inc. Acquires US Rights to Ameluz® and RhodoLED®, Secures $11 Million Investment

23andMe Sold to TTAM Research Institute for $305 Million

Fujirebio Acquires Plasma Services Group, Strengthening its Biomaterials Supply

RyboDyn Joins Lilly Gateway Labs to Advance Next-Gen Immunotherapies

Pierre Fabre Laboratories Acquires Worldwide Rights for PFL-721 and PFL-241, Expanding its Oncology Portfolio

Medtronic Announces MiniMed as Name for Planned New Diabetes Company

BioNTech to Acquire CureVac in $1.25 Billion All-Stock Acquisition

Quell Therapeutics and AstraZeneca Advance CAR-Treg Cell Therapy for Inflammatory Bowel Disease

Sanofi Acquires Vigil Neuroscience to Expand Alzheimer's Disease Pipeline

CRISPR and Sirius Therapeutics Partner to Develop siRNA Therapies for Thromboembolic Disorders

Carlyle and SK Capital Complete Acquisition of bluebird bio

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics